Page 11 - Harbor Statement News Today

Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and efficacy topline analysis includes sequential organ failure assessment (SOFA) scores and mortality for the 28-day period post treatment.Efficacy: Stand-alone analysis of the Allocetra™-treated patients, of which 78% had septic shock and 65% had invasive ventilation at screening, demonstrated substantial reductions in SOFA scores and 65% reduction in overal...

Digital Clarity Announces Strategic Alliance with Leading Transformation ...

/PRNewswire/ -- Kona Gold Beverages, Inc. (OTCPK: KGKG), a prominent holding company specializing in cutting-edge product development within the better-for-you...

Ideal Power Receives Order from Global Leader in Power Semiconductor ...

NEW YORK, April 09, 2024 -- INNOVATE Corp. , a diversified holding company, announced today that its Board of Directors has extended the subscription period for its rights offering to 5:00 p.m....

Leading digital out-of-home CTV platform for businesses partners with Adnimation to increase ad revenue and diversify demand sources ...

Cabot Corporation announced today that it will release operating results for the second quarter of fiscal 2024 on Monday, May 6, 2024, after market close. The Company will host a conference call and...

Fortune Rise Acquisition Corporation Receives April Monthly Extension ...

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colonAll NaviCap™ devices perfo...

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon